BioNTech Completes $1.25B All-Stock Purchase of Vaccine Competitor CureVac

BioNTech Completes $1.25B All-Stock Purchase of Vaccine Competitor CureVac

BioNTech Completes $1.25B All-Stock Purchase of Vaccine Competitor CureVac